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Abstract
Background—In May 2014, Dr. Francis Collins, the director of US National Institutes of Health, 
and Dr. Janine Clayton, the director of the US National Institutes of Health Office of Research on 
Women’s Health (ORWH) published a commentary in the journal Nature announcing new policies 
to ensure that preclinical research funded by the NIH consider both males and females. While 
these policies are still developing, they have already generated great interest by the scientific 
community and triggered both criticism and applause. This review provides a description and 
interpretation of the NIH guidelines and it traces the history that led to their implementation. As 
expected, this NIH initiative generated some anxiety in the scientific community. The use of 
female animals in the investigation of basic mechanisms is perceived to increase variability in the 
results, and the use of both sexes has been claimed to slow the pace of scientific discoveries and to 
increase the cost at a time characterized by declining research support.
Purpose—This review discusses issues related to the study of sex as a biological variable in 
alcohol studies and provides examples of how researchers have successfully addressed some of 
them. A practical strategy is provided to include both sexes in biomedical research while 
maintaining control of the research direction.
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Conclusion—The inclusion of sex as an important biological variable in experimental design, 
analysis and reporting of preclinical alcohol research is likely to lead to a better understanding of 
alcohol pharmacology and the development of alcohol use disorder, may promote drug discovery 
for new pharmacotherapies by increasing scientific rigor, and may provide clinical benefit to 
women’s health. This review aims to promote the understanding of the NIH sex as biological 
variable guidelines and to provide alcohol researchers with a theoretical and practical framework 
for working with both sexes in preclinical research.
Keywords
cell and animal studies; ethanol; gender; policy; preclinical research
1. The National Institute of Health policy on consideration of sex as a 
biological variable
In 2014, National Institute of Health (NIH) leaders raised concerns regarding an over-
reliance on male animals in preclinical research—particularly for diseases occurring more 
frequently in women and for diseases that manifest differently in men and women (Clayton 
and Collins, 2014). They noted that such biases could mislead future clinical studies and 
ultimately, clinical practice and argued that NIH needed to promote balanced representation 
of both sexes in preclinical research. Plans for future policies drew feedback from the 
scientific community supporting the view that consideration of sex as a biological variable 
(SABV) could potentially influence the reproducibility, rigor, and generalizability of 
research findings in biomedical research. Perhaps not surprisingly, the scientific community 
favored giving scientists the discretion to decide when and how to address SABV, such that 
consideration of SABV would be evaluated on a case-by-case basis in grant applications and 
peer-reviewed publications (see http://orwh.od.nih.gov/about/director/pdf/
RFIFinalReport20150520.pdf for full analysis of public comments).
NIH expects that SABV will be factored into research designs, analyses and reporting in 
vertebrate animal and human studies to the fullest extent possible. When proposing to study 
only one sex, investigators will be expected to justify their decision from the scientific 
literature, preliminary data, or other relevant considerations. Clearly, single sex studies are 
appropriate for the study of sex-specific conditions or phenomena such as maternal behavior 
or ovarian or prostate cancer. In addition, there are research topics—such as aggression in 
males—for which single sex studies can be scientifically appropriate. Resource scarcity and 
expense may also legitimately limit the ability to study both sexes, as in the case of non-
human primate research.
The result is that exclusive use of male subjects as a default will no longer be acceptable in 
NIH-supported preclinical research. That said, NIH does not intend to require that every 
NIH-supported preclinical study include equivalent numbers of males and females in every 
experiment. Moreover, the anticipated policy also does not stipulate that sex differences be 
the focus of every study. Rather, NIH will require that investigators address the possibility 
that sex could influence the study’s primary dependent variables in the study design and 
reporting. The NIH does not provide specific examples of when both sexes should be tested 
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and when a single sex is sufficient, as this could curtail the process of thinking through how 
SABV may affect the research hypothesis under consideration. Nevertheless, it is clear that 
the research topic will influence how SABV is likely to be considered in alcohol research. 
For example, in preclinical pharmacotherapy studies and other translational studies, it will 
be important to determine whether the experimental findings apply to both sexes. For other 
areas, simply including both sexes in the study will be sufficient to permit the discovery of 
any dramatic, unanticipated sex influences that could then be further pursued in studies 
adequately designed to characterize that apparent sex difference. At the same time, note that 
some sex differences that emerge may not be meaningful or interesting. For example, sex-
dependent body-size differences could affect activity in behavioral testing apparatuses 
without influencing the main variables of interest; in such cases, it would be sufficient to 
simply note the observation. Of course, there are many areas where sex is already 
recognized as a crucial influence such that many alcohol researchers routinely study both 
sexes. These examples illustrate the need for a nuanced approach that takes into 
consideration the practices and priorities within the various research domains supported by 
NIH to ensure the appropriate consideration of SABV.
How will NIH’s expectations be fulfilled? NIH will clarify and revise grant application 
instructions and review criteria to enhance reproducibility of research findings through 
increased scientific rigor and transparency. Consideration of sex and other relevant 
biological variables is among the new focuses of the revised review criterion instructions. 
Thus, grant applicants will be asked to explain how relevant biological variables, such as 
sex, are factored into research designs and analyses in the Research Strategies section. 
Consideration of SABV will be evaluated in the context of the overall research plan. In this 
way, scientists with detailed understanding of their respective fields will be in the best 
position to both formulate appropriate scenarios for accounting for SABV and to critically 
evaluate whether others are doing so sufficiently. The policies to be implemented in January 
2016 are discussed further in the following NIH Guide Notices (http://grants.nih.gov/grants/
guide/notice-files/NOT-OD-15-102.html; http://grants.nih.gov/grants/guide/notice-files/
NOT-OD-15-103.html).
Understandably, introducing new variables into the peer-review mix can provoke anxiety. 
Yet, in light of the potentially important sex influences in the diverse landscape of biological 
and behavioral research supported by the NIH, relevant subject matter experts are best 
qualified to evaluate whether SABV considerations are appropriate in the context of overall 
research goals. To facilitate this approach, the NIH Office of Research on Women’s Health 
(ORWH) is providing guidance to the scientific community (see http://orwh.od.nih.gov/
sexinscience/index.asp) and the NIH Center for Scientific Review is providing training to 
scientific review officers and study section chairs. The 2015 Research Society on 
Alcoholism round table discussion (on which this critical review was based) also contributed 
to these goals as applied to alcohol-related research, as will future discussions on this topic.
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2. Historical research perspective leading to the NIH policy
a. Historical perspective on clinical studies
The landmark clinical studies of the 1950–1980, such as the Physicians Health Study 
(1988b, 1988a, 1989), Multiple Risk Factor Intervention Trial (MRFIT) (1982), and the first 
20 years of the Baltimore Longitudinal Study of Aging all excluded women. Ironically, the 
first-ever clinical evaluation of estrogen treatment for cardiovascular disease was in a study 
that only enrolled males (Canner et al., 1986). The reasons for excluding women were 
varied, ranging from evidence-based (such that at the time coronary disease was seen mostly 
in men), or the overcautious (as in women of reproductive age should be excluded due to 
unanticipated effects on future or current pregnancies), to the downright quirky (as in 
restroom facilities were not available for women on the premises).
Recognition of sex-dependent differences in drug responses led to NIH actively seeking to 
ensure that studies took into consideration sex and gender differences in design and analysis 
leading to the NIH Revitalization Act, signed into law in 1993. This bill required that 
women and minorities be included in appropriate numbers in NIH-supported research and 
that NIH clinical trials be designed to identify differences in research outcomes between 
women and men. This bill was motivated by the recognition that although NIH’s internal 
guidelines urged that women be included in clinical trials, this policy was not adequately and 
systematically implemented during the grant review process. To address the disparity in sex 
representation in NIH funded research, the NIH ORWH was established. Over the span of 
the following two decades much progress has been made. Currently, approximately half of 
all participants in NIH-supported clinical research are female subjects. In 2003 (10 years 
following the NIH Revitalization Act), enrollment of women in Phase III clinical trials, 
excluding studies that are female only or male only, was more than 50% and more recently 
is reported to be 62.1% (FY2012).
However, there continues to be concern about the low inclusion of women in diseases that 
were traditionally thought to be male-centric, such as cardiovascular disease. Recent studies 
show that by age 40, cardiovascular disease prevalence is fairly equal among males and 
females and by 60, more women than men are affected (reviewed in (Kim and Menon, 
2009). In contrast, an analysis of female enrollment in National Heart, Lung, and Blood 
Institute funded studies from 1996 to 2006 showed an average of 27% women enrollment 
(Kim et al., 2008). Why the discrepancy? Unfortunately, an overwhelming majority of drug 
trials for cardiovascular disease are performed by pharmaceutical industries, which is 
regulated ultimately by the Food and Drug Administration (FDA), where an old guideline 
specifically excluded women of reproductive age in such studies (Merkatz, 1998). A 2000 
amendment to the Clinical Hold policy, however, now permits FDA to stop investigational 
new drugs studies for treatment of a serious or life-threatening disease if women or men are 
excluded due to reproductive potential (Clinical Hold for Products intended for life 
threatening conditions; 21 CFR 312.42(b)v). Nevertheless, poor inclusion of women in these 
studies is made worse by the fact that few studies use sex-based analyses (Geller et al., 
2011), so that all data are analyzed together instead of being disaggregated for sex/gender.
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Inclusion of female subjects in clinical research has led to better appreciation of the 
differences in responses to drugs between males and females. Sex differences may underlie 
adverse drug reactions affecting the heart, in particular cardiotoxicity and drug-induced long 
QT syndrome; the latter consists in a delayed repolarization of the heart after contraction 
and is associated with greater incidence of ventricular arrhythmias leading to cardiac arrest 
or sudden death (Hreiche et al., 2008). The role of sex hormones was suggested by the 
greater susceptibility to these adverse drug reactions during the ovulatory phase of the 
menstrual cycle (Rodriguez et al., 2001). Additional sex-related differences in responses to 
anesthetics and chemotherapeutic agents have also been identified. Female hormones have 
been reported to modulate opioid receptor density and dopaminergic function, with 
consequent impacts on respiratory depression and chronic pain (Nicolson et al., 2010). Sex 
hormones can modulate the γ-aminobutyric acid (GABA) receptor, a common site of 
anesthetic drugs, leading to sexually dimorphic effects of anesthetics (Frye and Duncan, 
1994). Clinical studies show that differential preventive effects are achieved with low-dose 
aspirin in women and men (Adelman et al., 2011). Similarly, Zolpidem, a drug used to treat 
insomnia, requires different dosing in women and men (Greenblatt et al., 2014).
b. The need for the inclusion of Sex as Biological Variable in preclinical studies’ guidelines
The recent (June 2015) announcement of the NIH Guide on the inclusion of SABV (see 
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-102.html) in biomedical 
research comes more than 20 years after the NIH Revitalization Act of 1993. In view of the 
efforts already underway, is the new NIH guideline on SABV for basic science studies 
necessary? Data gathered by the NIH ORWH indicates that female inclusion lags in basic 
science studies even as it has improved in clinical studies. The upshot is that the inclusion of 
both sexes may occur for the first time when a drug or procedure goes to clinical trial.
Preclinical research studies continue to rely heavily on male animals and/or omit reporting 
of the sex of animal subjects. The problem with this is that preclinical or cell-based studies 
are meant to precede or inform clinical trial design. Without adequate understanding of sex-
specific differences in disease processes or therapeutic responses, the generalizability of 
research findings is limited. Inclusion of both sexes in preclinical research is anticipated to 
improve data reproducibility and to identify potential differences in drug responses between 
males and females at earlier steps in translation.
Nearly all common diseases exhibit some degree of sex bias, whether male preponderant or 
female. In the case of neurologic diseases, multiple sclerosis is 3 times more likely to occur 
in females than males, while Parkinson’s disease is 2 times more likely to occur in males as 
compared to females. While overt sex bias in disease incidence is well known, the extent of 
sex bias in basic biological processes is only now beginning to be appreciated. Microarray 
analysis of 23,574 mouse gene transcripts revealed that the extent of sexual dimorphism in 
gene expression was much greater than previously recognized. The majority of active genes 
were sexually dimorphic in at least three tissues: liver (87%), adipose (88%), and muscle 
(66%) (Yang et al., 2006). The link between adiposity and chronic disease such as 
hypertension, cancer and diabetes is well established in men, but this connection is less well 
understood in women. Furthermore, fat deposition in women differs from men in the 
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premenopausal years but resembles that of men in the postmenopausal years (Palmer and 
Clegg, 2015), revealing a complex age-by-sex variation for this tissue. Curiously, the 
proportion of sexually dimorphic active gene expression in the brain was low compared to 
other tissues (14.6%) (Yang et al., 2006), despite the sex bias sometimes seen in brain 
function, neuroanatomy and the incidence of neurologic diseases such as Alzheimer’s 
disease, Parkinson’s disease, multiple sclerosis and stroke.
As recently as 5 years ago, an analysis of 2000+ biomedical studies published in 2009 
showed a male bias in 80% of the studies (Beery and Zucker, 2011). As expected there was 
variation based on disciplines so that the most male-biased fields were neuroscience (5.5:1, 
male: female) while a female bias occurred in reproduction-related journals. The ratio of 
male to female inclusion in studies was also greater for females in immunology-related 
journals; however this was offset by the fact that over 60% of the papers in this area simply 
did not report which sex was studied. At the present time the majority of journals do not 
insist on explicit information on which sex is used for cell or animal studies, resulting in a 
situation where single sex studies on males predominate. Even in dual sex studies, many 
studies are not disaggregated for sex, a problem endemic to both clinical and preclinical 
studies.
3. Myths and realities about the use of both sexes in preclinical research 
and suggested courses of action on how to balance sex in cell and animal 
studies
While the lack of equal usage of males and females in experimental studies is not disputed, 
the reasons for this are complicated. A recent paper (McCarthy, 2015) summarizes the many 
concerns biomedical researchers express regarding the use of both sexes, such as increasing 
the cost of the study, quadrupling animal numbers due to female estrous cycles necessitating 
a group for every phase of the cycle, or distracting from other important variables such as 
age. The issue of cost is certainly critical, but even without the inclusion of both sexes; 
investigators are making critical decisions about cost containment. Ultimately, these and 
related cost issues will and should drive the discussion for increased NIH budgets, both 
overall and at the level of the individual grant. For instance, the current modular grant may 
need to be revised to cope with increased experimental demands.
Another element of resistance to the incorporation of both sexes in preclinical studies is the 
notion that this somehow distracts from the main goal of the research program, making the 
research a “study of sex differences” as opposed to a “study of the disease.” One problem 
with this mindset is that SABV is often a key factor in the manifestation or progression of a 
disease. Essentially, this resistance requires a shift in attitude from considering the use of 
both sexes as a burdensome addition to one where inclusion of both sexes is simply good 
science. Inclusion of both sexes should be treated within the purview of experimental design 
– an integral part of the research study, as necessary as a control group or a drug dosage 
group or an age group. Hence, at its root, investigators need to be convinced that the SABV 
guidelines are meant to increase rigor in science, to add robustness to experimental design 
and, ultimately, to better inform clinical trials that are based on these studies.
Guizzetti et al. Page 6













One commonly held misconception that has contributed to the exclusion of female animals 
in research studies is that results in females are much more variable, in part due to hormonal 
fluctuations across the estrous or menstrual cycle (Cahill, 2006, Prendergast et al., 2014). 
Because daily tracking of vaginal cytology across the 4–5 day estrous cycle in rodents was 
viewed as time consuming and expensive, particularly if females were tested at each of the 
four stages of the estrous cycle, females were often excluded from research studies. 
However, the results from two different meta-analyses, one of pain-related traits (Mogil and 
Chanda, 2005) and one of behavioral, morphological, physiological, and molecular traits 
(Prendergast et al., 2014), provide strong evidence that variability in females is not 
significantly greater than males for any endpoint that was examined. A recent preliminary 
analysis of published neuroscience literature suggests that female rats are also not inherently 
more variable than male rats on a range of neuroscience-related outcomes (Becker et al., 
2015). An interesting finding from the Prendergast meta-analysis is that group housing 
compared to individual housing significantly increased variability in both male and female 
mice by 37%, suggesting that housing conditions (i.e., group size within a cage) contribute 
greater variation across studies than stage of estrous cycle (Prendergast et al., 2014).
Collectively, these results indicate that the initial examination of sex differences for a 
particular phenotype in neuroscience research does not require monitoring of the estrous 
cycle in female rodents. Strategies for assessing the role of estrous cycle stage have been 
published (McCarthy et al., 2012, Becker et al., 2005), but the initial recommendation is to 
measure adult females independent of estrous cycle stage. It also is important to search the 
existing literature – are there reports that phenotype female subjects to determine whether 
the genotype and species to be tested may exhibit estrous or menstrual cycle differences in 
the trait of interest? While the lack of published studies may just represent the paucity of 
data available on this topic, if published phenotyping of female subjects does not reveal 
estrous or menstrual cycle differences or such studies are not available, then a reasonable 
first approach is to initially ignore the estrous/menstrual cycle and determine whether there 
is a basic sex difference in one male group versus one female group (McCarthy et al., 2012).
We have outlined this practical approach in Figure 1, with the first step to obtain results from 
males and females. When the initial assessment of sex difference reveals that variability in 
females is greater than in males, or if existing data indicate that a particular trait of interest is 
known to vary as a function of the estrous or menstrual cycle, the investigator is faced with 
the decision of whether or not to mechanistically pursue these differences, which will likely 
require additional funding and will make sex differences a major area of research for the 
laboratory. It is important to emphasize that researchers retain the power to decide whether 
to investigate sex differences and/or estrous cycle-dependent changes in females, as 
indicated by the diamond shapes in the flow-chart shown in Figure 1. If investigators, after 
identifying a sexually dimorphic response, decide to continue their research in only one sex, 
this decision should be rationalized in the context of their scientific findings. For instance, if 
different behaviors are affected by alcohol in males and females, the decision to focus future 
studies only on one sex should be based on a clearly stated rationale about why the 
investigator is interested in that specific behavior; therefore, the choice is about the scientific 
question to be pursued, not about whether to use male or female animals. Indeed, this 
approach is more “scientific” and thoughtful than the more traditional approach to use male 
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animals as the “default” animal models. Furthermore, as sexually dimorphic effects are 
published, other laboratories have the opportunity to follow up on these newly identified, but 
not pursued, sex differences.
If the investigator decides to explore sex differences identified during her/his studies, 
comparison between one group of intact males and a minimum of two groups of intact 
females at known estrous cycle stages is a recommended option (Becker et al., 2005, Beery 
and Zucker, 2011, McCarthy et al., 2012). Available publications provide useful and detailed 
descriptions on the determination of estrous cycle phase in the rodent (Becker et al., 2005) 
and of the vaginal cytology of the rat and mouse estrous cycle (Cora et al., 2015). An 
alternate strategy would be to do vaginal smears to assess estrous cycle stage or to take a 
blood sample to asses estradiol levels on the day that a specific measure (behavioral, 
electrophysiological, etc) is taken or at the termination of the study when brains and other 
tissues are collected, and then use estrous cycle stage or estradiol levels as a covariate in the 
analysis.
When comparing males and females, it is important to consider the biology and age of the 
subject as well as the housing environment during development, time of day for testing, and 
the appropriate measurement of the trait of interest, because it is incorrect to assume that any 
observed sex difference will generalize to other ages or conditions (Becker et al., 2005). 
Once a sex difference has been identified, subsequent studies can be conducted to identify 
the factors that contribute to the trait difference in males and females (Becker et al., 2005, 
McCarthy et al., 2012). Considering that a majority of sex differences are identified in 
adulthood, these series of experiments would allow the investigator to determine whether the 
sex difference is determined by steroid hormones in adulthood, whether it is the 
consequence of developmental exposure to steroid hormones, or whether it is due to a direct 
sex chromosome effect. A straightforward way to begin is to determine if a sex difference is 
eliminated by gonadectomy and restored by steroid hormone replacement. Alternately, 
mechanistic studies that are focused on neurotransmitters or neuropeptides and downstream 
signaling molecules can be conducted to pursue the sex difference, but interpretation of the 
results will likely need to consider the modulatory influence of steroid hormones and actions 
at nuclear or membrane steroid receptors.
Another misconception is that studies utilizing primary cultures do not need to consider the 
sex of the animal. However, every neuron, glia, and other cell type carries the complement of 
male chromosomes (XY) or female chromosomes (XX), and there are hormone-independent 
mechanisms for sex differences that are under the control of the sex chromosome 
complement (Becker et al., 2005, Jazin and Cahill, 2010, McCarthy, 2015, McCarthy et al., 
2012).
As a result, the NIH SABV guidelines should be interpreted as a recommendation that 
studies utilizing primary cultures should plate separately cells derived from male and female 
tissue. One approach is to plate cells from individual rodent pups; later, the sex of the 
individual pups used to prepare the cultures can be confirmed with PCR by genotyping for 
male-specific sex-determining region Y (Sry) (McClive and Sinclair, 2001). Another 
approach is to separate beforehand male and female pups or fetuses based on genital papilla 
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size/anogenital distance (Greenham and Greenham, 1977, McCarthy et al., 2012). 
Veterinarians attending animal facilities at any given institution can be asked to train 
laboratory personnel on this simple task. The reliability of this method is very high in 
adequately trained people; this method can be validated by PCR analysis of Sry.
A possible course of action for in vitro studies is to test the initial hypothesis in sex-specific 
cultures; if different effects are found, the investigator should make the decision of whether 
to carry out more in-depth mechanistic studies in cultures derived from one sex or whether 
to study both sexes and unravel the sex difference mechanism. This decision should be based 
on scientific findings, questions, and interests. If no sex differences are found, the 
investigator can easily justify the use of mixed-sex cultures in future studies.
The importance of examining sex differences with primary cultures is highlighted by the 
recent findings that female (but not male) mice exhibit astrocyte reactivity following chronic 
ethanol exposure and withdrawal in vivo and in in vitro sex-specific primary astrocyte 
cultures (Wilhelm et al., 2015). Thus, use of sex-specific primary cultures has the potential 
to increase the translational value of in vitro findings and to facilitate the comparison with in 
vivo work.
4. Examples of sex differences in alcohol research
There are many examples of sex differences in clinical and preclinical alcohol research as 
alcohol exposure throughout life has been shown to have sexually dimorphic effects. 
Discussion of all these studies is beyond the focus of this article, but excellent reviews have 
been published on sex differences on the developing brain in prenatal (Weinberg et al., 2008) 
and adolescent (Kuhn, 2015, Spear, 2015) models of ethanol exposure as well as on every 
stage of alcohol addiction in adult animals (Becker and Koob, 2016). While we refer readers 
to those more comprehensive reviews on the topic of sex differences in alcohol responses, 
we describe here one mechanistic example of how alcohol may affect differently males and 
females at the molecular level with the goal to emphasize that the assumption that research 
carried out in one sex can be generalized to both sexes is unwarranted.
Research in rodent models document that females consume higher doses of ethanol than 
males in a variety of ethanol access conditions (Cozzoli et al., 2014b, Finn et al., 2004, 
Juarez and Barrios de Tomasi, 1999, Middaugh and Kelley, 1999, Middaugh et al., 1999, 
Sinnott et al., 2002, Yoneyama et al., 2008, Lancaster and Spiegel, 1992), but this is partially 
due to an effect of testosterone to reduce intake (Vetter-O’Hagen et al., 2011) and there is 
minimal evidence for an influence of estrous cycle phase on ethanol intake or self-
administration. In particular, lower ethanol consumption was observed during proestrus in 
early work in female rats (Forger and Morin, 1982), but this finding was not replicated in 
later studies in freely cycling female rats (Ford et al., 2002, Roberts et al., 1998, van Haaren 
and Anderson, 1994) and was only observed in females whose cycles had been synchronized 
(in this case, the lower ethanol self-administration was observed primarily in estrus and 
proestrus) (Roberts et al., 1998) or when microanalysis of ethanol intake patterns were 
examined (with higher bout frequency but lower bout size in proestrus) (Ford et al., 2002). 
Consequently, sex differences in ethanol consumption are typically examined without 
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monitoring estrous cycle stage, with similar variance in results for both male and female 
rodents.
Data from the Finn laboratory illustrate a potential mechanism underlying sex differences in 
the regulation of ethanol drinking involving differences in metabotropic glutamate receptor 5 
(mGlu5) signaling. This study examined the biological implication of sexually divergent 
changes in the effect of repeated binge drinking on signaling molecules downstream of 
mGlu5 in adult male and female C57BL/6J mice (Figure 2A). Initial studies determined that 
the mGlu5 antagonist MTEP [3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine] was equally 
effective to decrease binge ethanol intake in male and female mice (Figure 2B), but that later 
ethanol intake after a period of abstinence was increased in females and unaltered in males 
(Cozzoli et al., 2014a). Thus, it is possible that male and female mice have similar sensitivity 
to mGlu5 antagonists at the receptor level while the signaling downstream of mGlu5 might 
differ between the sexes. Based on evidence that glutamatergic signaling molecules in the 
nucleus accumbens are sensitive to the neuroadaptive properties of ethanol (Ary et al., 2012, 
Besheer et al., 2010, Cozzoli et al., 2012, Cozzoli et al., 2009, Goulding et al., 2011, Marty 
and Spigelman, 2012, Neasta et al., 2010, Neasta et al., 2011), the next studies determined 
whether there were sex differences in the effect of repeated binge ethanol consumption on 
protein levels of signaling molecules in the phosphoinositide 3-kinase (PI3K) signaling 
cascade (Figure 2A). Notably, 24-hour withdrawal from repeated binge ethanol consumption 
significantly altered the phosphorylation of PI3K, mammalian target of rapamycin (mTOR), 
4E-binding protein 1 and p70 ribosomal protein S6 kinase in the accumbens of male but not 
female mice (Cozzoli et al., 2016). To study the functional ramifications of the observed sex-
specific alteration, mTOR was targeted because repeated binge drinking produced a 
divergent response in protein levels. Bilateral infusion of the mTOR inhibitor rapamycin into 
the accumbens established that mTOR inhibition did not alter binge ethanol intake in 
females, whereas it produced a dose-dependent and selective reduction in binge ethanol 
intake in males (Figure 2C) (Cozzoli et al., 2016). Together, the results highlight that mTOR 
signaling in the accumbens is necessary to maintain binge ethanol consumption only in male 
mice. Because mTOR complex 1 is proposed to be a common point of neuronal signaling 
that is important for drug-induced plasticity (Neasta et al., 2014), the resistance of female 
mice to the ability of rapamycin to decrease binge drinking emphasizes the sex specificity of 
potential pharmacotherapies for alcohol use disorders.
4. Balancing sex in animal and cell studies in drug development
The percentage of drugs that fail clinical trials is extremely high, approaching 90%, 
according to a recent study (Hay et al., 2014). As a logical approach aimed at reducing the 
enormous cost associated with failed clinical trials, the NIH intends to increase the rigor and 
reproducibility of preclinical studies by introducing the SABV guidelines and related 
policies. Rodent and non-rodent mammalian models are used to delineate the 
pharmacokinetic profile and general safety of potential drugs, as well as to identify toxicity 
patterns of drugs during drug development. Animal models are used to determine the drug’s 
half-life, which depends on rate of absorption, volume of distribution, metabolism, and 
excretion properties – all of which can be influenced by the sex of the animal. Evidence that 
sex differences in these parameters exist in animal models suggests that accounting for 
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SABV in physiological responses will lead to better experimental study design. Particularly 
in translational studies leading to clinical trials, important factors that contribute to 
variability in pharmacokinetics include sex-dependent differences in body weight, plasma 
volume, gastric emptying time, plasma protein levels, enzymatic activity, drug transporter 
function, and excretion activity. Several of these differences are present in rodent models. 
For example, gastric alcohol dehydrogenase activity is higher in male than in female rats 
(Aasmoe and Aarbakke, 1999), which would impact blood ethanol concentrations after oral 
administration. Moreover, cytochrome P450 levels (i.e., CYP3A9 and CYP4Fs) show higher 
mRNA and protein expression in livers of females versus male rats (Aasmoe and Aarbakke, 
1999, Kalsotra et al., 2002), which may also impact ethanol metabolism. Other factors 
involved in drug metabolism are less well understood from the perspective of sex 
differences. Para-aminohippuric acid (PAH), a reference substance used to estimate renal 
organic anion transport, has a lower rate of clearance and excretion rate in female rats 
compared to male rats (Cerrutti et al., 2002b, Cerrutti et al., 2002a), which would be relevant 
in establishing dosing and frequency of drugs using this mechanism of excretion.
Drug development for alcohol use disorder is relatively unexplored compared to other 
diseases such as cancer, cardiovascular and psychiatric disorders (Litten et al., 2012). One 
barrier is the lack of information of how SABV may impact the molecular target(s) by which 
alcohol exerts its pharmacologic activity. However, in addition to efficacy, one needs to 
consider sex differences in toxicology when developing a new pharmacotherapy for alcohol 
use disorder. For example, the half-life of perfluorooctanoic acid, which is excreted in the 
kidney by an organic anion transporter, is 70 times longer in male than in female rats and 
this effect is modified by changes in sex hormone levels (Vahter et al., 2007). Another 
example of a classically direct sex hormone effect on P450 is CYP2J5 in the mouse kidney, 
which is up-regulated by testosterone and down-regulated by estrogen (Vahter et al., 2007). 
Changes in clearance and metabolism will alter the response between the sexes, particularly 
in the exaggerated doses given in toxicological studies.
5. Concluding Remarks
Starting on January 2016, investigators are required by NIH to consider SABV in research 
designs, analyses, and reporting in preclinical studies or to provide a solid rationale (based 
on scientific considerations or other relevant factors) supporting the decision to study only 
one sex. The inclusion of sex in the biological variables that are accounted for in preclinical 
studies is expected to increase rigor and reproducibility in the preclinical findings and to 
facilitate the successful translation of these findings into the clinic. Based on the sex 
differences already known in alcohol consumption, metabolism and pharmacology, it is 
likely that inclusion of SABV in preclinical experimental design can help to advance 
pharmacotherapeutic development for alcohol use disorder. Many concerns associated with 
the use of both sexes in animal research involve resource management. Figure 1 depicts a 
suggested flowchart that may be useful when designing experiments in accordance with the 
SABV guidelines and intends to emphasize how researchers retain the power to decide 
whether to investigate sex differences and/or estrous cycle-dependent changes in females.
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The SABV guidelines can be interpreted as intending to challenge researchers to rethink the 
“default” models mostly used in preclinical research, which are male animals and mixed-sex 
primary cultures, and to prevent unwarranted generalizations of results obtained in only one 
sex. In this context, it is apparent how these guidelines have the potential to increase the 
rigor of preclinical results that may lead to an increased number of drugs going successfully 
through clinical trials.
Acknowledgments
This work was supported by Department of Veterans Affairs Merit Review Awards BX001819 (MG) and 
BX001070 (DAF); and by the National Institutes of Health R01AA021468 (MG), R21AA021876 (MG), 
R01AA022948 (MG), R01AA12439 (DAF), P60AA011605 (DLR), U24AA020024 (DLR), P60 AA09803 (PM), 
R01 AA022448 (DLD). Additionally, this material is the result of work supported with resources and the use of 
facilities at the VA Portland Health Care System (MG and DAF).
References
Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk 
factor changes and mortality results. Jama. 1982; 248:1465–1477. [PubMed: 7050440] 
Findings from the aspirin component of the ongoing Physicians’ Health Study. The New England 
journal of medicine. 1988a; 318:262–264. [PubMed: 3275899] 
The physicians’ health study: aspirin for the primary prevention of myocardial infarction. The New 
England journal of medicine. 1988b; 318:924–926. [PubMed: 3352679] 
Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin 
component of the ongoing Physicians’ Health Study. The New England journal of medicine. 1989; 
321:129–135. [PubMed: 2664509] 
Aasmoe L, Aarbakke J. Sex-dependent induction of alcohol dehydrogenase activity in rats. 
Biochemical pharmacology. 1999; 57:1067–1072. [PubMed: 10796077] 
Adelman EE, Lisabeth L, Brown DL. Gender differences in the primary prevention of stroke with 
aspirin. Women’s health. 2011; 7:341–352. quiz 352–343. 
Ary AW, Cozzoli DK, Finn DA, Crabbe JC, Dehoff MH, Worley PF, Szumlinski KK. Ethanol up-
regulates nucleus accumbens neuronal activity dependent pentraxin (Narp): implications for 
alcohol-induced behavioral plasticity. Alcohol. 2012; 46:377–387. [PubMed: 22444953] 
Becker JB, Arnold AP, Berkley KJ, Blaustein JD, Eckel LA, Hampson E, Herman JP, Marts S, Sadee 
W, Steiner M, Taylor J, Young E. Strategies and methods for research on sex differences in brain 
and behavior. Endocrinology. 2005; 146:1650–1673. [PubMed: 15618360] 
Becker JB, Koob GF. Sex Differences in Animal Models: Focus on Addiction. Pharmacological 
reviews. 2016; 68:242–263. [PubMed: 26772794] 
Becker JB, Liang JW, Prendergast BJ. Female rats liberated for neuroscience research. Neuroscience. 
2015; 2015:344–306.
Beery AK, Zucker I. Sex bias in neuroscience and biomedical research. Neuroscience and 
biobehavioral reviews. 2011; 35:565–572. [PubMed: 20620164] 
Besheer J, Grondin JJ, Cannady R, Sharko AC, Faccidomo S, Hodge CW. Metabotropic glutamate 
receptor 5 activity in the nucleus accumbens is required for the maintenance of ethanol self-
administration in a rat genetic model of high alcohol intake. Biological psychiatry. 2010; 67:812–
822. [PubMed: 19897175] 
Cahill L. Why sex matters for neuroscience. Nature reviews. Neuroscience. 2006; 7:477–484. 
[PubMed: 16688123] 
Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year 
mortality in Coronary Drug Project patients: long-term benefit with niacin. Journal of the 
American College of Cardiology. 1986; 8:1245–1255. [PubMed: 3782631] 
Guizzetti et al. Page 12













Cerrutti JA, Brandoni A, Quaglia NB, Torres AM. Sex differences in p-aminohippuric acid transport in 
rat kidney: role of membrane fluidity and expression of OAT1. Molecular and cellular 
biochemistry. 2002a; 233:175–179. [PubMed: 12083373] 
Cerrutti JA, Quaglia NB, Brandoni A, Torres AM. Effects of gender on the pharmacokinetics of drugs 
secreted by the renal organic anions transport systems in the rat. Pharmacological research. 2002b; 
45:107–112. [PubMed: 11846621] 
Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature. 2014; 509:282–
283. [PubMed: 24834516] 
Cora MC, Kooistra L, Travlos G. Vaginal Cytology of the Laboratory Rat and Mouse: Review and 
Criteria for the Staging of the Estrous Cycle Using Stained Vaginal Smears. Toxicologic 
pathology. 2015; 43:776–793. [PubMed: 25739587] 
Cozzoli DK, Courson J, Caruana AL, Miller BW, Greentree DI, Thompson AB, Wroten MG, Zhang 
PW, Xiao B, Hu JH, Klugmann M, Metten P, Worley PF, Crabbe JC, Szumlinski KK. Nucleus 
accumbens mGluR5-associated signaling regulates binge alcohol drinking under drinking-in-the-
dark procedures. Alcoholism, clinical and experimental research. 2012; 36:1623–1633.
Cozzoli DK, Goulding SP, Zhang PW, Xiao B, Hu JH, Ary AW, Obara I, Rahn A, Abou-Ziab H, Tyrrel 
B, Marini C, Yoneyama N, Metten P, Snelling C, Dehoff MH, Crabbe JC, Finn DA, Klugmann M, 
Worley PF, Szumlinski KK. Binge drinking upregulates accumbens mGluR5-Homer2-PI3K 
signaling: functional implications for alcoholism. The Journal of neuroscience : the official journal 
of the Society for Neuroscience. 2009; 29:8655–8668. [PubMed: 19587272] 
Cozzoli DK, Kaufman KR, Nipper MA, Hashimoto JG, Wiren KM, Finn DA. Functional regulation of 
PI3K-associated signaling in the accumbens by binge alcohol drinking in male but not female 
mice. Neuropharmacology. 2016; 105:164–174. [PubMed: 26773198] 
Cozzoli DK, Strong-Kaufman MN, ATM, Hashimoto JG, Wiren KM, Finn DA. The effect of mGluR5 
antagonism during binge drinking on subsequent ethanol intake in C57BL/6J mice: Sex- and age-
induced differences. Alcoholism, clinical and experimental research. 2014a; 38:730–738.
Cozzoli DK, Tanchuck-Nipper MA, Kaufman MN, Horowitz CB, Finn DA. Environmental stressors 
influence limited-access ethanol consumption by C57BL/6J mice in a sex-dependent manner. 
Alcohol. 2014b; 48:741–754. [PubMed: 25459519] 
Finn DA, Sinnott RS, Ford MM, Long SL, Tanchuck MA, Phillips TJ. Sex differences in the effect of 
ethanol injection and consumption on brain allopregnanolone levels in C57BL/6 mice. 
Neuroscience. 2004; 123:813–819. [PubMed: 14751275] 
Ford MM, Eldridge JC, Samson HH. Microanalysis of ethanol self-administration: estrous cycle phase-
related changes in consumption patterns. Alcoholism, clinical and experimental research. 2002; 
26:635–643.
Forger NG, Morin LP. Reproductive state modulates ethanol intake in rats: effects of ovariectomy, 
ethanol concentration, estrous cycle and pregnancy. Pharmacology, biochemistry, and behavior. 
1982; 17:323–331.
Frye CA, Duncan JE. Progesterone metabolites, effective at the GABAA receptor complex, attenuate 
pain sensitivity in rats. Brain research. 1994; 643:194–203. [PubMed: 8032914] 
Geller SE, Koch A, Pellettieri B, Carnes M. Inclusion, analysis, and reporting of sex and race/ethnicity 
in clinical trials: have we made progress? Journal of women’s health. 2011; 20:315–320.
Goulding SP, Obara I, Lominac KD, Gould AT, Miller BW, Klugmann M, Szumlinski KK. Accumbens 
Homer2-mediated signaling: a factor contributing to mouse strain differences in alcohol drinking? 
Genes, brain, and behavior. 2011; 10:111–126.
Greenblatt DJ, Harmatz JS, Singh NN, Steinberg F, Roth T, Moline ML, Harris SC, Kapil RP. Gender 
differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual 
administration. Journal of clinical pharmacology. 2014; 54:282–290. [PubMed: 24203450] 
Greenham LW, Greenham V. Sexing mouse pups. Laboratory animals. 1977; 11:181–184. [PubMed: 
886831] 
Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates 
for investigational drugs. Nature biotechnology. 2014; 32:40–51.
Hreiche R, Morissette P, Turgeon J. Drug-induced long QT syndrome in women: review of current 
evidence and remaining gaps. Gender medicine. 2008; 5:124–135. [PubMed: 18573480] 
Guizzetti et al. Page 13













Jazin E, Cahill L. Sex differences in molecular neuroscience: from fruit flies to humans. Nature 
reviews. Neuroscience. 2010; 11:9–17. [PubMed: 20019686] 
Juarez J, Barrios de Tomasi E. Sex differences in alcohol drinking patterns during forced and voluntary 
consumption in rats. Alcohol. 1999; 19:15–22. [PubMed: 10487383] 
Kalsotra A, Anakk S, Boehme CL, Strobel HW. Sexual dimorphism and tissue specificity in the 
expression of CYP4F forms in Sprague Dawley rats. Drug metabolism and disposition: the 
biological fate of chemicals. 2002; 30:1022–1028. [PubMed: 12167568] 
Kim ES, Carrigan TP, Menon V. Enrollment of women in National Heart, Lung, and Blood Institute-
funded cardiovascular randomized controlled trials fails to meet current federal mandates for 
inclusion. Journal of the American College of Cardiology. 2008; 52:672–673. [PubMed: 
18702973] 
Kim ES, Menon V. Status of women in cardiovascular clinical trials. Arteriosclerosis, thrombosis, and 
vascular biology. 2009; 29:279–283.
Kuhn C. Emergence of sex differences in the development of substance use and abuse during 
adolescence. Pharmacology & therapeutics. 2015; 153:55–78. [PubMed: 26049025] 
Lancaster FE, Spiegel KS. Sex differences in pattern of drinking. Alcohol. 1992; 9:415–420. [PubMed: 
1418667] 
Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, Falk DE, Moss H, Huebner R, Noronha A. 
Medications development to treat alcohol dependence: a vision for the next decade. Addiction 
biology. 2012; 17:513–527. [PubMed: 22458728] 
Marty VN, Spigelman I. Effects of alcohol on the membrane excitability and synaptic transmission of 
medium spiny neurons in the nucleus accumbens. Alcohol. 2012; 46:317–327. [PubMed: 
22445807] 
McCarthy MM. Incorporating Sex as a Variable in Preclinical Neuropsychiatric Research. 
Schizophrenia bulletin. 2015; 41:1016–1020. [PubMed: 26067001] 
McCarthy MM, Arnold AP, Ball GF, Blaustein JD, De Vries GJ. Sex differences in the brain: the not 
so inconvenient truth. The Journal of neuroscience : the official journal of the Society for 
Neuroscience. 2012; 32:2241–2247. [PubMed: 22396398] 
McClive PJ, Sinclair AH. Rapid DNA extraction and PCR-sexing of mouse embryos. Molecular 
reproduction and development. 2001; 60:225–226. [PubMed: 11553922] 
Merkatz RB. Inclusion of women in clinical trials: a historical overview of scientific, ethical, and legal 
issues. Journal of obstetric, gynecologic, and neonatal nursing : JOGNN / NAACOG. 1998; 
27:78–84.
Middaugh LD, Kelley BM. Operant ethanol reward in C57BL/6 mice: influence of gender and 
procedural variables. Alcohol. 1999; 17:185–194. [PubMed: 10231166] 
Middaugh LD, Kelley BM, Bandy AL, McGroarty KK. Ethanol consumption by C57BL/6 mice: 
influence of gender and procedural variables. Alcohol. 1999; 17:175–183. [PubMed: 10231165] 
Mogil JS, Chanda ML. The case for the inclusion of female subjects in basic science studies of pain. 
Pain. 2005; 117:1–5. [PubMed: 16098670] 
Neasta J, Barak S, Hamida SB, Ron D. mTOR complex 1: a key player in neuroadaptations induced by 
drugs of abuse. Journal of neurochemistry. 2014; 130:172–184. [PubMed: 24666346] 
Neasta J, Ben Hamida S, Yowell Q, Carnicella S, Ron D. Role for mammalian target of rapamycin 
complex 1 signaling in neuroadaptations underlying alcohol-related disorders. Proceedings of the 
National Academy of Sciences of the United States of America. 2010; 107:20093–20098. 
[PubMed: 21041654] 
Neasta J, Ben Hamida S, Yowell QV, Carnicella S, Ron D. AKT signaling pathway in the nucleus 
accumbens mediates excessive alcohol drinking behaviors. Biological psychiatry. 2011; 70:575–
582. [PubMed: 21549353] 
Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity. Trends in pharmacological 
sciences. 2010; 31:108–114. [PubMed: 20117848] 
Palmer BF, Clegg DJ. The sexual dimorphism of obesity. Molecular and cellular endocrinology. 2015; 
402:113–119. [PubMed: 25578600] 
Prendergast BJ, Onishi KG, Zucker I. Female mice liberated for inclusion in neuroscience and 
biomedical research. Neuroscience and biobehavioral reviews. 2014; 40:1–5. [PubMed: 24456941] 
Guizzetti et al. Page 14













Roberts AJ, Smith AD, Weiss F, Rivier C, Koob GF. Estrous cycle effects on operant responding for 
ethanol in female rats. Alcoholism, clinical and experimental research. 1998; 22:1564–1569.
Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in 
women during the menstrual cycle. Jama. 2001; 285:1322–1326. [PubMed: 11255387] 
Sinnott RS, Phillips TJ, Finn DA. Alteration of voluntary ethanol and saccharin consumption by the 
neurosteroid allopregnanolone in mice. Psychopharmacology. 2002; 162:438–447. [PubMed: 
12172699] 
Spear LP. Adolescent alcohol exposure: Are there separable vulnerable periods within adolescence? 
Physiology & behavior. 2015; 148:122–130. [PubMed: 25624108] 
Vahter M, Gochfeld M, Casati B, Thiruchelvam M, Falk-Filippson A, Kavlock R, Marafante E, Cory-
Slechta D. Implications of gender differences for human health risk assessment and toxicology. 
Environmental research. 2007; 104:70–84. [PubMed: 17098226] 
van Haaren F, Anderson K. Sex differences in schedule-induced alcohol consumption. Alcohol. 1994; 
11:35–40. [PubMed: 8142066] 
Vetter-O’Hagen CS, Sanders KW, Spear LP. Evidence for suppressant effects of testosterone on sex-
typical ethanol intake in male Sprague-Dawley rats. Behavioural brain research. 2011; 224:403–
407. [PubMed: 21726585] 
Weinberg J, Sliwowska JH, Lan N, Hellemans KG. Prenatal alcohol exposure: foetal programming, the 
hypothalamic-pituitary-adrenal axis and sex differences in outcome. Journal of 
neuroendocrinology. 2008; 20:470–488. [PubMed: 18266938] 
Wilhelm CJ, Hashimoto JG, Roberts ML, Bloom SH, Andrew MR, Wiren KM. Astrocyte dysfunction 
induced by alcohol in females but not males. Brain Pathol. 2015 Epub ahead of print. 
Yang X, Schadt EE, Wang S, Wang H, Arnold AP, Ingram-Drake L, Drake TA, Lusis AJ. Tissue-
specific expression and regulation of sexually dimorphic genes in mice. Genome research. 2006; 
16:995–1004. [PubMed: 16825664] 
Yoneyama N, Crabbe JC, Ford MM, Murillo A, Finn DA. Voluntary ethanol consumption in 22 inbred 
mouse strains. Alcohol. 2008; 42:149–160. [PubMed: 18358676] 
Guizzetti et al. Page 15














Flow-chart of a potential course of action when designing experiments that use animals of 
both sexes. A major misconception that has contributed to the exclusion of female animals in 
research studies is that results in females are much more variable and that tracking of vaginal 
cytology across the estrous cycle is necessary to reduce this variability. Results from meta-
analyses indicated that variability in females on most biological measurements is not 
significantly greater than males (Becker et al., 2015, Mogil and Chanda, 2005, Prendergast 
et al., 2014). Researchers that work with both sexes advise to initially ignore the estrous/
menstrual cycle and to first determine whether there is a basic sex difference in one male 
group versus one female group (McCarthy et al., 2012). This flow-chart shows how research 
can be developed after collecting data from males and females on any given end-point of 
interest. Ovals represent the start (red) or the end (green) points of the chart; the 
parallelograms represent outputs; the rectangle represents a process (action); and the 
diamonds indicate decisions to be made. After obtaining results from males and females (in 
which estrous cycle has not been monitored), the results are analyzed to determine whether 
females are more variable than males. More likely, females and males will present similar 
variability; at this point, data will be analyzed to identify whether there is a sex difference in 
the response. If no sex differences are found, data are reported. If sex differences are 
identified, the investigator is presented with the decision (left diamond) of whether to pursue 
them, in which case she/he will formulate new hypotheses and apply for new funding, or 
whether to simply report them and pursue other research. In the less-likely event that data 
from females present a much higher variability than data from males, the investigator is 
presented with the decision (right diamond) of whether to pursue the biological mechanism 
behind this variability, consider the estrous cycle and hormonal fluctuations and apply for 
new funding for this research, or whether to not pursue this finding and analyze and report 
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the data obtained from males and females as described before. This figure intends to 
emphasize how the researcher retains the power to decide whether to investigate sex 
differences and/or estrous cycle-dependent changes in females. After analyzing the results 
for sex differences and reporting them, the investigator has the choice of using one or both 
sexes for future studies by providing a convincing rationale based on scientific findings, 
questions, and interests. In this contest, the NIH SABV guidelines discourage the use of a 
given sex as the “default” model to be used in research.
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Pharmacological manipulation of binge drinking reveals that male and female mice have 
similar sensitivity to a metabotropic glutamate receptor 5 (mGlu5) antagonist at the receptor 
level (B) but different sensitivity to rapamycin (C) an inhibitor of mTOR, consistent with the 
sexually divergent changes in phosphoinositide 3-kinase (PI3K) and downstream signaling 
molecules following repeated binge drinking (A). Panel A: Depicted is a simplified diagram 
of mGlu1/5 intracellular signaling. Downstream signaling molecules that differ by sex and 
influence alcohol binge drinking are highlighted in bold font. Notably, 24-hour withdrawal 
from repeated binge drinking significantly altered the phosphorylation of PI3K, mTOR, 4E-
binding protein 1 (4EBP1) and p70 ribosomal protein S6 kinase (P70 S6K) and tended to 
alter phosphoinositide-dependent protein kinase 1 (PDK) in the nucleus accumbens of male 
but not female mice (results in Cozzoli et al., 2016). Panel B: Binge ethanol consumption, 
averaged across seven 30-min sessions, following intraperitoneal injection of saline or 
different doses of MTEP. The efficacy of MTEP to decrease binge drinking was similar in 
the male and female mice, as the 20 mg/kg MTEP dose significantly decreased binge 
ethanol intake by 33% or 31% in the male and female mice, respectively. Values are the 
mean ± SEM for the number of animals on the figure. **p<0.01 versus respective saline 
group; adapted from (Cozzoli et al., 2014a). Panel C: Intra-accumbens rapamycin dose-
dependently decreased binge ethanol intake during a 30-min binge session in male but not 
female mice, with a 28% decrease in binge ethanol intake following the 100 ng/side dose in 
male mice. Mice received bilateral infusions of vehicle or rapamycin prior to a binge ethanol 
session in a within-subjects design. Values are the mean ± SEM for the number of animals 
on the figure. *p<0.05, **p<0.01 versus vehicle infusion; line represents significant 
ANOVA; adapted from (Cozzoli et al., 2016).
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